Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

Posted On: 2026-07-17

Health & Lifestyle Health Daily Digest Online News

Singapore, July 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): Curie Oncology (Farrer) National Cancer Centre National University Hospital OncoCare Cancer Centre (Novena) Oncocare Cancer Centre (Gleneagles)

Trial Status: NA

Principal Investigator(s): Dr Choo Su Pin Dr Koo Si-Lin Dr Glori...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)